ClinConnect ClinConnect Logo
Search / Trial NCT03538639

Vascular Disease Discovery Protocol

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · May 25, 2018

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Etiology Of Rare And Orphan Diseases With Vascular Phenotype Natural History Of Rare And Orphan Diseases With Vascular Phenotype Pathophysiology Of Uncommon Vascular Diseases Undiagnosed Diseases Rare Human Diseases With Vascular Features Natural History

ClinConnect Summary

The Vascular Disease Discovery Protocol is a clinical trial designed to study heart and blood vessel diseases, especially those linked to genetic factors. Researchers want to gather information from individuals who have these conditions, their family members, and healthy volunteers. This study aims to better understand how genetic mutations and predispositions can affect vascular health, which is crucial since heart and blood diseases are the leading causes of death and disability in the U.S.

To participate, individuals aged 2 and older who may have a genetic heart or blood vessel disease, as well as their relatives and healthy volunteers, are welcome. Participants will go through a series of tests and evaluations, which may include medical history reviews, physical exams, and various imaging tests. They might also provide samples of blood, urine, or saliva. Each participant’s experience will vary, with some visits lasting just a few hours while others may take longer. Overall, this trial is a step towards better understanding and possibly improving the treatment of vascular diseases.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • All subjects must be between the ages of 2-100 years old.
  • Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.
  • Unaffected related pregnant women (including spouses/partners) for cord blood and tissue collection (surgical waste) only at the time of delivery.
  • EXCLUSION CRITERIA:
  • Healthy volunteers unable to give informed consent
  • Healthy volunteers who decline to have blood drawn and/or tissue studies or who do not consent to have samples stored for future research.
  • Cognitively impaired individuals who are not affected.
  • Cognitively impaired individuals not related to affected subjects.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Manfred Boehm, M.D.

Principal Investigator

National Heart, Lung, and Blood Institute (NHLBI)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials